Clinical guidance from both the American College of Obstetricians and Gynecologists and the Substance Abuse and Mental Health Services Administration includes recommendations for medications for opioid use disorder (MOUD) in lieu of supervised withdrawal to improve outcomes and reduce the risk of relapse. In this workshop, we will discuss the clinical use of MOUD in pregnant patients to include methadone, buprenorphine, buprenorphine/naloxone, buprenorphine extended-release injection, and naltrexone extended-release injection. We will educate the audience regarding clinical indications for use, dosing and dosing adjustments, adverse effects, and clinical outcomes. We will review several challenging clinical cases requiring audience participation. Our clinical expertise will be compared with the audience’s experience with pregnant patients on MOUD in various settings. The goal is to solidify audience knowledge to become more comfortable prescribing and managing pregnant patients on MOUD to increase availability of this treatment option and improve outcomes.Skill-Building Exercises – incorporating tools such as hands-on training, quizzes, toolkits, worksheets, facilitated small group discussions or breakouts., Case Discussion - Use of cases to engage the audience in brainstorming about diagnosis, treatment planning, clinical issues.